Understanding Disparities in AD
Practical Dermatology: Atopic DermatitisUnderstanding Disparities in AD
DermWire TV Extra: 3-Year Clinical Data on Lebrikizumab
Practical Dermatology: Atopic DermatitisDermWire TV Extra: 3-Year Clinical Data on Lebrikizumab
New Drugs Helping AD Catch Up to Psoriasis
Practical Dermatology: Atopic DermatitisNew Drugs Helping AD Catch Up to Psoriasis
Addressing the Unique Challenges of AD Patients
Practical Dermatology: Atopic DermatitisAddressing the Unique Challenges of AD Patients
FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
Practical Dermatology: Atopic DermatitisFDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
- 02/25/2025
News
View all